XML 35 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Contract Acquisition Costs
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue and Contract Acquisition Costs Revenue and Contract Acquisition Costs
The following table summarizes the Company’s disaggregated revenue:
Years Ended December 31,
(in millions)202320222021
U.S.$1,251.0 $884.8 $651.5 
International410.1 363.0 359.9 
Total Omnipod Products1,661.1 1,247.8 1,011.4 
Drug Delivery36.0 57.5 87.4 
Total revenue$1,697.1 $1,305.3 $1,098.8 
The percentages of total revenue for customers that represent 10% or more of total revenue was as follows:
Years Ended December 31,

202320222021
Distributor A28%19%*
Distributor B24%16%*
Distributor C19%17%12%
* Represents less than 10% of revenue for the period.
Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:
As of December 31,
(in millions)20232022
Accrued expenses and other current liabilities$15.4 $16.1 
Other liabilities1.9 1.6 
Total deferred revenue$17.3 $17.7 
Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:
As of December 31,
(in millions)202320222021
Deferred revenue recognized$16.0 $2.1 $4.4 
Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown:
As of December 31,
(in millions)20232022
Prepaid expenses and other current assets$16.6 $15.2 
Other assets32.0 31.3 
Total capitalized contract acquisition costs, net$48.6 $46.5 
The Company recognized $16.3 million, $14.6 million, and $12.3 million of amortization of capitalized contract acquisition costs for the years ended December 31, 2023, 2022, and 2021, respectively.